The CPHI China 2024 kicked off with grandeur at the Shanghai New International Expo Centre on June 19th. Sunrise Group, a globally renowned pharmaceutical manufacturer and distributor, participated in this event to actively explore new partnerships and market opportunities.

China, the world's second-largest pharmaceutical market, showcases its immense industry potential and substantial market demand at this premier event, which features over 3,500 exhibitors from both domestic and international backgrounds and is expected to attract nearly 100,000 visitors. The exhibition serves as a crucial platform for innovation and collaboration, aiding Chinese pharmaceutical companies in expanding their global networking possibilities.

Among the exhibitors, Sunrise Group (Booth W2A32) has garnered significant acclaim. The company offers a diverse array of products in pharmaceuticals, agrochemicals, and veterinary medicines, sparking extensive discussions among industry professionals about pharmaceutical raw materials and intermediates. Sunrise Group also provides exceptional warehousing and logistics services, including repackaging, labeling, blending, and analytical testing. These services are designed to create a "last-mile" supply chain solution for chemical end-users. 

Looking ahead, Sunrise Group aims to further its global expansion by forging strong partnerships to foster innovation. The company's goal is to deliver top-notch products and premium services to customers worldwide, playing a pivotal role in advancing the pharmaceutical sector on a global scale. Stay tuned for more updates from Sunrise Group.